GSK and Pfizer announce merger of medicines without prescription

The British pharmaceutical companies GSK (GlaxoSmithKline) and American Pfizer announced on Wednesday the merger of its activities of nonprescription medicines, which will create a company with a turnover of 12.7 billion dollars. "GSK concluded an agreement with Pfizer to combine your activity in a joint venture of amplitude, with revenue of 9.8 billion pounds (12.7 billion dollars)," the company announced in a statement. "GSK will have most of the control, 68%, and Pfizer 32% in this company," the British Lab's note. Pfizer issued a statement with the same information. The agreement includes drugs such as anti-inflammatory Voltaren, acetaminophen Panadol and Sensodyne, among other products. Pfizer provides for the new company the Painkiller Advil, Centrum and Caltrate vitamins and other medications. To be achieved, the creation of the new company needs the approval of the shareholders of GSK and the authorization of the authorities governing competition. GSK provides that the merger will become effective in the second half of 2019.